Clinical Trial

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase III clinical trial to evaluate the efficacy and safety of XZP-3287 in combination with Fulvestrant versus placebo combined with Fulvestrant in Patients who have HR positive and Her2 negative recurrent/metastatic breast cancer and have received prior endocrine therapy are eligible for study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-09-30; most recent amendment 2024-05-22.
Status change: Recruiting → Active, Not Recruiting 2024-05-22
Status change: Not Yet Recruiting → Recruiting 2022-01-04
Trial Details
NCT Number NCT05077449
Lead Sponsor Xuanzhu Biopharmaceutical Co., Ltd.
Conditions Advanced Breast Cancer
Enrollment 300 participants
Start Date 2021-11-16
Primary Completion 2024-02-22 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2024-05-24